Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

Insilico MedicineInsilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

New investors, including a large, diversified asset management firm on the US West Coast and BHR Partners joined the round, along with current investors, including lead investor of Series C financing round Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. Insilico's founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.

Capital raised in the round will further bolster Insilico's financial position and fuel the growth of its advancing pipeline, including its lead program which is currently in a Phase I study, and continued development of its Pharma.AI platform. The proceeds will also fund ongoing global expansion and planned strategic initiatives, including a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement Insilico's vast curated data assets.

"Despite unprecedented market conditions in the biotechnology sector, we raised this Series D round from several of the most reputable US-based and global investors," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "It is a testament to the strength of our end-to-end AI platform, which has been validated by many partners, and produced our first novel antifibrotic program discovered using AI and aging research, and designed using our generative AI chemistry engine. This unique program completed a first-in-human Phase 0 study in healthy volunteers and has entered Phase I clinical trials. We have also nominated seven preclinical candidates across a number of other disease indications since 2021. I am very excited about this progress and have decided to personally invest in this round."

"The application of artificial intelligence and machine learning for drug discovery has incredible potential to transform the way new therapies are developed," said Min Fang, Managing Director, Head of China Healthcare at Warburg Pincus. "For Insilico, 2022 is a year of incredible growth and progress. They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery. We're delighted to continue to partner with the Insilico team and support a company that is at the forefront of this innovation."

Since the previous round of financing, Insilico has developed a growing portfolio in frontier areas empowered by its proprietary AI platform. Seven programs in its internal pipeline have progressed to the IND-enabling stage, including a novel 3CL protease inhibitor for COVID-19 treatment, and two synthetic lethality programs targeting MAT2A and USP1 for oncology. It also successfully completed a Phase 0 microdose study and entered a Phase I clinical trial with its first internally developed program targeting fibrosis.

"With the power of cutting-edge AI platforms developed fully in house and validated by many global pharmaceutical companies and our innovative, highly parallel, fully distributed drug discovery model, we nominated seven preclinical candidates since I joined the company in 2021," said Feng Ren, PhD, Insilico's Chief Scientific Officer and Head of Global Research and Development. "I have 15 years of experience working in large pharmaceutical companies and CROs and I am impressed by the speed and quality of our discovery programs. We plan to continue expanding the breadth of the pipeline and enhance our AI and robotics capabilities globally. Our rapidly growing team is composed of talented and experienced scientists in drug discovery with diverse backgrounds and relentless passion for novelty and innovation, and fully committed to developing novel drugs with a sense of urgency for the waiting patients."

Insilico has also expanded its collaborations with the pharmaceutical industry through co-development and software licensing deals with a number of major pharmaceutical companies. Since the launch of its PandaOmics™ and Chemistry42™ in late 2020, nine out of the top 20 pharmaceutical companies have licensed Insilico's AI platforms. In 2022, Insilico signed a multi-asset partnership deal with Fosun Pharma in January, and a drug discovery co-development deal with EQRx in March. Notably, Insilico achieved its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy in less than 40 days into the strategic collaboration with Fosun Pharma.

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

https://insilico.com

Most Popular Now

Bayer Launches New Healthy-Aging Ecosyst…

Combining a scientifically formulated dietary supplement, a leading-edge wellness companion app, and a saliva-based a biological age test by Chronomics, Bayer is taking a big step in the emerging healthy-aging...

Airwave Healthcare Expands Team with Fra…

Patient stimulus technology provider Airwave Healthcare has appointed Francesca McPhail, who will help health and care providers achieve more from their media and entertainment systems for people receiving care. Francesca McPhail...

Scientists Use AI to Detect Chronic High…

Researchers at Klick Labs unveiled a cutting-edge, non-invasive technique that can predict chronic high blood pressure (hypertension) with a high degree of accuracy using just a person's voice. Just published...

New AI-Driven Tool could Revolutionize B…

Researchers at the Icahn School of Medicine at Mount Sinai have developed a noninvasive technique that could dramatically improve the way doctors monitor intracranial hypertension, a condition where increased pressure...

ChatGPT Outperformed Trainee Doctors in …

The chatbot ChatGPT performed better than trainee doctors in assessing complex cases of respiratory disease in areas such as cystic fibrosis, asthma and chest infections in a study presented at...

Former NHS CIO Will Smart Joins Alcidion

A former national chief information officer for health and social care in England, Will Smart will join the Alcidion Group board in a global role from October. He will provide...

The Darzi Review: The NHS "Is in Se…

Lyn Whitfield, content director at Highland Marketing, takes a look at Lord Darzi's review of the NHS, immediate reaction, and next steps. The review calls for a "tilt towards technology...

Can Google Street View Data Improve Publ…

Big data and artificial intelligence are transforming how we think about health, from detecting diseases and spotting patterns to predicting outcomes and speeding up response times. In a new study analyzing...

Healthcare Week Luxembourg: Second Editi…

1 - 2 October 2024, Luxembourg.Save the date: Healthcare Week Luxembourg is back on 1 and 2 October 2024 at Luxexpo The Box. Acclaimed last year by healthcare professionals from...

SPARK TSL Appoints David Hawkins as its …

SPARK TSL has appointed David Hawkins as its new sales director, to support take-up of the SPARK Fusion infotainment solution by NHS trusts and health boards. SPARK Fusion is a state-of-the-art...

AI Products Like ChatGPT can Provide Med…

The much-hyped AI products like ChatGPt may provide medical doctors and healthcare professionals with information that can aggravate patients' conditions and lead to serious health consequences, a study suggests. Researchers considered...

One in Five UK Soctors use AI Chatbots

A survey led by researchers at Uppsala University in Sweden reveals that a significant proportion of UK general practitioners (GPs) are integrating generative AI tools, such as ChatGPT, into their...